Income statement
EUR
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 339M | 316M | 285M | 315M | 160M |
| Gross Profit | 64M | 32M | 22M | 26M | 14M |
| Operating Income | 27M | 16M | 9M | 12M | 4M |
| EBITDA | 33M | 23M | 16M | 18M | 6M |
| Net Income | 16M | 10M | 4M | 9M | 7M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$11.73
+0.00% today
Window Change
+0.00%
Window
Jun 23, 2025 → Apr 6, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 198 bars · Jun 23, 2025 → Apr 6, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
M1 Kliniken AG (MKLNF) is a Healthcare stock with a market cap of $214.81M and listed on OTC. The stock last traded around $11.73 and up 0.0% across the available one-year price window (Jun 23, 2025 → Apr 6, 2026). Baseline metrics include revenue growth of +7.2%, EPS growth of +59.3%, a dividend yield of 2.9%. What stands out right now is revenue +7.2%, EPS +59.3%, free cash flow +334.6% with operating margin 8.5% and ROIC 12.4%. The dividend matters to the case here, with a current yield around 2.9%. Valuation is more restrained than many high-expectation growth names at P/E 18.2 and price/sales 0.9. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines MKLNF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
MKLNF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
MKLNF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for MKLNF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$159.6M
-49.3% YoY
FY Net Income
$6.8M
-23.4% YoY
Free Cash Flow
$7.9M
-44.6% YoY
Revenue Growth
+7.2%
EPS Growth
+59.3%
Gross Margin
12.0%
Net Margin
5.0%
Income statement
EUR
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 339M | 316M | 285M | 315M | 160M |
| Gross Profit | 64M | 32M | 22M | 26M | 14M |
| Operating Income | 27M | 16M | 9M | 12M | 4M |
| EBITDA | 33M | 23M | 16M | 18M | 6M |
| Net Income | 16M | 10M | 4M | 9M | 7M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 21M | 22M | 35M | 38M | 22M |
| Total Assets | 188M | 213M | 197M | 198M | 189M |
| Total Liabilities | 54M | 70M | 54M | 58M | 73M |
| Shareholder Equity | 106M | 113M | 96M | 95M | 86M |
| Total Debt | 10M | 11M | 20M | 31M | 39M |
| Net Debt | -11M | -12M | -15M | -7M | 17M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
9M
-40.1% YoY
Capital Expenditures
1M
-8.3% YoY
Free Cash Flow
8M
-44.6% YoY
Key ratios
Gross Margin
12.0%
Operating Margin
8.5%
Net Margin
5.0%
ROE
15.8%
Debt / Equity
0.18x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.